Formycon Raises Fresh Capital To Drive Biosimilar Development
Funding For COVID-19 Also Received
German biosimilars firm Formycon has raised tens of millions of euros through an issue of new shares, with the cash earmarked for its burgeoning pipeline of wholly-owned biosimilars, including a Lucentis (ranibizumab) candidate being developed with Coherus.
